EN | TR
E-ISSN: 2147-2653
Evaluation of Patient Satisfaction, Back Pain, and Bone Mineral Densitometry T-Scores in Patients with Postmenopausal Osteoporosis Who Received Denosumab Treatment
PDF
Cite
Share
Request
Original Investigation
VOLUME: 27 ISSUE: 3
P: 165-169
December 2021

Evaluation of Patient Satisfaction, Back Pain, and Bone Mineral Densitometry T-Scores in Patients with Postmenopausal Osteoporosis Who Received Denosumab Treatment

Turk J Osteoporos 2021;27(3):165-169
DOI: 10.4274/tod.galenos.2020.91249
Gonca Sağlam 1
Dilek Çetinkaya Alişar 2
1. Karadeniz Teknik Üniversitesi Tıp Fakültesi, Fiziksel Tıp ve Rehabilitasyon Anabilim Dalı, Trabzon, Türkiye
2. Kocaeli Devlet Hastanesi, Fiziksel Tıp ve Rehabilitasyon Kliniği, Kocaeli, Türkiye
No information available.
No information available
Received Date: 09.11.2020
Accepted Date: 24.12.2020
Publish Date: 28.12.2021
PDF
Cite
Share
Request

ABSTRACT

Objective:

This study aimed to determine the effects of denosumab therapy on bone mineral densitometry (BMD) T-scores, back pain, and satisfaction in patients with postmenopausal osteoporosis.

Materials and Methods:

This study included 134 patients diagnosed with postmenopausal osteoporosis and regularly received denosumab treatment for 2 years. Socio-demographic data were collected, and patients were evaluated after denosumab therapy in BMD T-scores and back pain improvement using a visual analog scale (VAS). Patient satisfaction, physical function improvement, and quality of life were analyzed using a Likert scale.

Results:

The pretreatment values revealed a statistically significant improvement in vertebral and femoral T-scores and back pain after treatment (p<0.001). The mean back pain VAS score reduced from 6.66±1.23 to 3.16±1.70. The mean vertebral L1-L4 T-scores increased from -3.32±0.45 to -2.98±0.49 (p<0.001), and femoral neck T-scores increased from -1.98±1.26 to -1.86±1.25 (p<0.001). Denosumab treatment was very satisfying for 26.87% of patients, whereas 47.76% of patients found it satisfying. In the improvement in physical functions, 36.57% of patients evaluated denosumab treatment as very effective and 32.09% as effective. Additionally, 28.36% of patients evaluated denosumab as very effective in regard to the quality of life, whereas 43.28% evaluated it as effective.

Conclusion:

Study results demonstrate that denosumab injection is a practical and satisfactory treatment option that effectively improves T-scores and back pain in postmenopausal osteoporosis treatment.

References

1
Clynes MA, Harvey NC, Curtis EM, Fuggle NR, Dennison EM, Cooper C. The epidemiology of osteoporosis. Br Med Bull 2020;133:105-17.
2
Gennari L, Merlotti D, Falchetti A, Eller Vainicher C, Cosso R, Chiodini I. Emerging therapeutic targets for osteoporosis. Expert Opin Ther Targets 2020;24:115-30.
3
Warriner AH, Saag KG. Osteoporosis diagnosis and medical treatment. Orthop Clin North Am 2013;44:125-35.
4
Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 2017;12:43.
5
Mcclung MR. Efficacy and Safety of Osteoporosis Treatment. In: Pocket Reference to Osteoporosis. Springer; Cham: 2019. p. 43-57.
6
Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, et al. American Association Of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis - 2016. Endocr Pract 2016;22(Suppl 4):1-42.
7
Deeks ED. Denosumab: A Review in Postmenopausal Osteoporosis. Drugs Aging 2018;35:163-73.
8
Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993;8:1137-48.
9
Kulaksızoğlu M. Denosumab in the Treatment of Osteoporosis. Turkiye Klinikleri J Endocrin-Special Topics 2017;10:95-100.
10
Wensel TM, Iranikhah MM, Wilborn TW. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. Pharmacotherapy 2011;31:510-23.
11
Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al (FREEDOM Trial). Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-65.
12
Lyu H, Jundi B, Xu C, Tedeschi SK, Yoshida K, Zhao S, et al. Comparison of Denosumab and Bisphosphonates in Patients With Osteoporosis: A Meta-Analysis of Randomized Controlled Trials. J Clin Endocrinol Metab 2019;104:1753-65.
13
Sheedy KC, Camara MI, Camacho PM. Comparison of the efficacy, adverse effects, and cost of zoledronic acid and denosumab in the treatment of osteoporosis. Endocr Pract 2015;21:275-9.
14
Freemantle N, Satram-Hoang S, Tang ET, Kaur P, Macarios D, Siddhanti S, et al. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 2012;23:317-26.
15
Kendler DL, McClung MR, Freemantle N, Lillestol M, Moffett AH, Borenstein J, et al. Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int 2011;22:1725-35.
16
Hiligsmann M, Dellaert BG, Dirksen CD, Watson V, Bours S, Goemaere S, et al. Patients’ preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment. Rheumatology (Oxford) 2017;56:1167-76.
17
Özsoy-Ünübol T, Akyüz G, Mirzayeva S, Güler T. Evaluation of pain, quality of life, and patient satisfaction in parenterally treated patients with postmenopausal osteoporosis. Turk J Phys Med Rehabil 2020;66:262-70.
18
Dempster DW. Osteoporosis and the burden of osteoporosis-related fractures. Am J Manag Care 2011;17 Suppl 6:S164-9.
19
Makras P, Vaiopoulos G, Lyritis GP; Greek National Medicine Agency. 2011 guidelines for the diagnosis and treatment of osteoporosis in Greece. J Musculoskelet Neuronal Interact 2012;12:38-42.
20
Hiligsmann M, Reginster JY. Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women. Bone 2010;47:34-40.
21
Albert SG, Reddy S. Clinical Evaluation of Cost Efficacy of Drugs for Treatment of Osteoporosis: A Meta-analysis. Endocr Pract 2017;23:841-56.
22
Adami S, Isaia G, Luisetto G, Minisola S, Sinigaglia L, Gentilella R, et al. Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study. J Bone Miner Res 2006;21:1565-70.
23
Ferrari S, Libanati C, Lin CJF, Brown JP, Cosman F, Czerwiński E, et al. Relationship Between Bone Mineral Density T-Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment. J Bone Miner Res 2019;34:1033-40.